----item----
version: 1
id: {46313E4E-5F4F-4490-8B65-891922B15A22}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/07/30/Ironwood Adds Viberzi To Its Bag
parent: {33D065F8-4841-41E4-809A-5D1E27443795}
name: Ironwood Adds Viberzi To Its Bag
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 38a4fdc5-8651-4de3-af75-8babb10d6333

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 32

Ironwood Adds Viberzi To Its Bag
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 32

Ironwood Adds Viberzi To Its Bag
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1411

<p><p>Allergan is building on its existing relationship with Ironwood to commercialize the irritable bowel syndrome drug <i>Viberzi</i> (eluxadoline), the pair announced on Aug. 5. </p><p>Viberzi was approved by FDA in late-May for the treatment of IBS with diarrhea (IBS-D). The drug is a mixed opioid receptor that acts as a mu receptor agonist, a delta receptor antagonist and a kappa receptor agonist. It <a href="http://#http://www.scripintelligence.com/policyregulation/Actavis-Viberzi-Valeants-Xifaxan-OKd-in-IBS-D-in-US-358630" target="_new">was approved</a> as a twice-daily, oral treatment.</p><p>Allergan and Ironwood had a previous agreement to commercialize Ironwood's <i>Linzess</i> (linaclotide) for IBS with constipation (IBS-C). Ironwood's specialty sales force of about 25,000 reps will add Allergan's Viberzi into its bag of products &ndash; Linzess will remain the lead product. The smaller biotech will be compensated for the volume of calls, as well as agreed upon performance metrics. Allergan will remain responsible for all other commercial costs. </p><p>"The Viberzi co-promotion agreement is a natural extension of Ironwood&rsquo;s focus on bringing innovative solutions to patients suffering from functional gastrointestinal disorders," said Ironwood's Chief Commercial Officer Tom McCourt, who sees this as a way to further strengthen Ironwood's position in the GI space. </p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 3

<p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 32

Ironwood Adds Viberzi To Its Bag
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150730T234855
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150730T234855
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150730T234855
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC029438
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{B17EB169-D816-450D-BAF5-3AEE9B8BC441}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 32

Ironwood Adds Viberzi To Its Bag
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{2D771726-4AE8-4124-B380-232612225CB7}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 9

Editorial
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

359706
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042432Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

38a4fdc5-8651-4de3-af75-8babb10d6333
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042432Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
